Orphazyme A/S
CSE:ORPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orphazyme A/S
Total Current Assets
Orphazyme A/S
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orphazyme A/S
CSE:ORPHA
|
Total Current Assets
kr19.3m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Assets
kr2.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
18%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Assets
kr15.7B
|
CAGR 3-Years
128%
|
CAGR 5-Years
62%
|
CAGR 10-Years
38%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Current Assets
$16.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Assets
€1.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
24%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Assets
kr6.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
See Also
What is Orphazyme A/S's Total Current Assets?
Total Current Assets
19.3m
DKK
Based on the financial report for Dec 31, 2023, Orphazyme A/S's Total Current Assets amounts to 19.3m DKK.
What is Orphazyme A/S's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-46%
Over the last year, the Total Current Assets growth was -66%. The average annual Total Current Assets growth rates for Orphazyme A/S have been -71% over the past three years , -46% over the past five years .
